rs138986552
Variant summary
Our verdict is Benign. Variant got -10 ACMG points: 2P and 12B. PM2BP4_StrongBP6_Very_Strong
The NM_139076.3(ABRAXAS1):c.917T>C(p.Val306Ala) variant causes a missense change. The variant allele was found at a frequency of 0.00017 in 1,614,062 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V306L) has been classified as Uncertain significance.
Frequency
Consequence
NM_139076.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -10 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
ABRAXAS1 | NM_139076.3 | c.917T>C | p.Val306Ala | missense_variant | 9/9 | ENST00000321945.12 | |
ABRAXAS1 | NM_001345962.2 | c.590T>C | p.Val197Ala | missense_variant | 8/8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
ABRAXAS1 | ENST00000321945.12 | c.917T>C | p.Val306Ala | missense_variant | 9/9 | 1 | NM_139076.3 | P1 |
Frequencies
GnomAD3 genomes ? AF: 0.000755 AC: 115AN: 152246Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000171 AC: 43AN: 251192Hom.: 0 AF XY: 0.000125 AC XY: 17AN XY: 135776
GnomAD4 exome AF: 0.000109 AC: 159AN: 1461698Hom.: 1 Cov.: 33 AF XY: 0.0000880 AC XY: 64AN XY: 727148
GnomAD4 genome ? AF: 0.000755 AC: 115AN: 152364Hom.: 0 Cov.: 33 AF XY: 0.000671 AC XY: 50AN XY: 74516
ClinVar
Submissions by phenotype
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 02, 2020 | Variant summary: FAM175A c.917T>C (p.Val306Ala) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00024 in 284830 control chromosomes, predominantly at a frequency of 0.0027 within the African or African-American subpopulation in the gnomAD database. The observed variant frequency within African or African-American control individuals in the gnomAD database is approximately 86 fold of the estimated maximal expected allele frequency (MPAF) for a pathogenic variant in FAM175A causing Hereditary Breast and Ovarian Cancer Syndrome phenotype (3.1e-05). In addition, this variant has been also reported in 9/2559 African American women (i.e. with an allele frequency of 0.0018 that is about 56 fold of the MPAF), who were older than age 70 years and cancer free in the FLOSSIES database. These data strongly suggest that the variant is a benign polymorphism found primarily in populations of African or African-American origin. Though the variant, c.917T>C, has been reported in the literature in an affected individual (Renault_2016), this report does not provide unequivocal conclusions about association of the variant with Hereditary Breast and Ovarian Cancer Syndrome. In addition, co-occurrences with other pathogenic variants have been reported (BRCA2 c.3922G>T (p.Glu1308X), and TP53 c.375G>A (p.Thr125Thr) in two internal LCA samples), providing supporting evidence for a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Another clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, and classified the variant as likely benign. Based on the evidence outlined above, the variant was classified as benign. - |
not provided Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Invitae | Dec 08, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at